OCALA, Fla. — October 7, 2026
AIM ImmunoTech highlighted its strategy to address treatment resistance in metastatic pancreatic cancer through a new BioTuesdays feature featuring CEO Thomas K. Equels. The feature examines the potential of Ampligen® (rintatolimod) as a maintenance therapy following first-line chemotherapy and outlines the scientific and clinical rationale supporting the company’s development strategy. AIM is evaluating Ampligen in combination with AstraZeneca’s Imfinzi® (durvalumab) in the DURIPANC clinical trial following chemotherapy. With final Ampligen dosing now complete, the company is preparing for the next stage of development while awaiting primary and secondary clinical endpoints. AIM said the program is focused on addressing the significant unmet need for maintaining disease control and potentially extending survival in patients with metastatic pancreatic cancer.
Ampligen Targets Immune Resistance in Pancreatic Cancer
A central element of AIM’s strategy is the potential for Ampligen to modify the immunosuppressive tumor microenvironment associated with pancreatic cancer. The company describes Ampligen as a double-stranded RNA and selective TLR3 agonist immunomodulator designed to stimulate immune activity. AIM is investigating whether this approach can help convert immunologically “cold” tumors into a more active immune environment and potentially improve the ability of checkpoint inhibitors to function. The strategy is being evaluated in the DURIPANC trial, which combines Ampligen with durvalumab following first-line chemotherapy. AIM said the completion of Ampligen dosing represents an important transition point for the program as the company moves toward analysis of clinical and biomarker data and evaluates a potential path into pivotal development.
Dutch Program Provides Exploratory Survival Observations
The BioTuesdays feature also discusses observations from a Netherlands-approved Named Patient Program (NPP) that provided Ampligen to patients with pancreatic cancer following FOLFIRINOX treatment. In an exploratory analysis of 39 patients with a neutrophil-to-lymphocyte ratio below 4.5, median overall survival was reported at 34.8 months, measured from the beginning of FOLFIRINOX. AIM said additional immune and tumor biomarkers were used to explore patient subgroups associated with favorable survival observations. The company emphasized that the Named Patient Program was not a controlled clinical trial, and comparisons with historical controls do not establish treatment efficacy. Nevertheless, AIM said the observations are helping inform its understanding of potential treatment response and future clinical trial design, including the identification of biomarkers that could potentially support patient selection in subsequent studies.
Advertisement
AIM Prepares for Potential Pivotal Development
AIM ImmunoTech is using the clinical observations, mechanistic research and biomarker findings to shape the next phase of its Ampligen pancreatic cancer program. The company said it holds patents covering Ampligen combinations with checkpoint inhibitors and has obtained pancreatic cancer orphan drug designations in the United States and European Union. Following completion of dosing in the DURIPANC study, AIM is awaiting reporting of the trial’s primary and secondary endpoints while evaluating potential pathways toward a pivotal Phase 3 study. The company is also considering financing and pharmaceutical partnership opportunities that could support later-stage development. AIM’s current strategy centers on determining whether Ampligen’s immunomodulatory mechanism can provide a clinically meaningful maintenance approach after chemotherapy for metastatic pancreatic cancer, where treatment resistance and limited therapeutic options remain major challenges.
Source::AIM ImmunoTech press release
